This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2009 by Banner Health.
Recruitment status was:  Recruiting
Information provided by:
Banner Health Identifier:
First received: November 17, 2008
Last updated: April 23, 2010
Last verified: December 2009
The purpose of this study is to assess the validity and reliability of an abstinence syndrome assessment tool used in pediatric patients with iatrogenic opioid dependence.

Substance Withdrawal Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation of a Pediatric Abstinence Syndrome Scoring Tool Utilizing a Standardized Hospital-Based Guideline for Iatrogenic Opioid Dependence

Further study details as provided by Banner Health:

Primary Outcome Measures:
  • Total scores of abstinence syndrome symptoms [ Time Frame: Up to 23 days ]

Secondary Outcome Measures:
  • Expert opinion on abstinence syndrome [ Time Frame: Up to 23 days ]

Estimated Enrollment: 75
Study Start Date: November 2009
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Limited continuous opioid exposure (at least 120 and less than 156 hours)
Extended continuous opioid exposure (156 hours or more)


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pediatric Intensive Care Unit patients

Inclusion Criteria:

  • Pediatric Intensive Care Unit patients ages 2 weeks to 18 years
  • Patients receiving continuous opioid infusions for 5 days (at least 120 hours) or more

Exclusion Criteria:

  • Attending discretion
  • Patients with deterioration of medical status requiring interventions of pain control, surgery, sedation, or re-intubation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00792415

Contact: Teri Reyburn-Orne, RN, MSN, PNP 480-512-3373

United States, Arizona
Cardon Children's Medical Center Recruiting
Mesa, Arizona, United States, 85202
Contact: Teri Reyburn-Orne, RN, MSN, PNP    480-512-7901   
Sub-Investigator: Tarek Youssef, MD, FAAP         
Sub-Investigator: Stephanie Nevins, MD         
Sub-Investigator: Keith Reitzel, MD         
Sub-Investigator: Rima Abdouni, PharmD         
Sponsors and Collaborators
Banner Health
Principal Investigator: Teri Reyburn-Orne, RN, MSN, PNP Banner Children's Hospital at Banner Desert Medical Center
  More Information

Responsible Party: Teri Reyburn-Orne, RN, MSN, CPNP-AC/Pediatric Pain Team Program Manager, Cardon Children's Medical Center Identifier: NCT00792415     History of Changes
Other Study ID Numbers: BHRI#05-08-0074
Study First Received: November 17, 2008
Last Updated: April 23, 2010

Keywords provided by Banner Health:
Abstinence syndrome symptoms
Withdrawal symptoms
Opioid dependence

Additional relevant MeSH terms:
Substance Withdrawal Syndrome
Pathologic Processes
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on September 21, 2017